| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.3 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.3 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.078 | 0.3 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | manumycin A | CTRPv2 | pan-cancer | AAC | 0.034 | 0.3 |